JP2011500562A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500562A5
JP2011500562A5 JP2010528867A JP2010528867A JP2011500562A5 JP 2011500562 A5 JP2011500562 A5 JP 2011500562A5 JP 2010528867 A JP2010528867 A JP 2010528867A JP 2010528867 A JP2010528867 A JP 2010528867A JP 2011500562 A5 JP2011500562 A5 JP 2011500562A5
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
compound according
compound
ring members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528867A
Other languages
English (en)
Japanese (ja)
Other versions
JP5591706B2 (ja
JP2011500562A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/011422 external-priority patent/WO2009048527A1/en
Publication of JP2011500562A publication Critical patent/JP2011500562A/ja
Publication of JP2011500562A5 publication Critical patent/JP2011500562A5/ja
Application granted granted Critical
Publication of JP5591706B2 publication Critical patent/JP5591706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528867A 2007-10-10 2008-10-03 置換ビフェニルgpr40調節因子 Expired - Fee Related JP5591706B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99878607P 2007-10-10 2007-10-10
US60/998,786 2007-10-10
US6872408P 2008-03-06 2008-03-06
US61/068,724 2008-03-06
PCT/US2008/011422 WO2009048527A1 (en) 2007-10-10 2008-10-03 Substituted biphenyl gpr40 modulators

Publications (3)

Publication Number Publication Date
JP2011500562A JP2011500562A (ja) 2011-01-06
JP2011500562A5 true JP2011500562A5 (https=) 2011-11-17
JP5591706B2 JP5591706B2 (ja) 2014-09-17

Family

ID=40338063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528867A Expired - Fee Related JP5591706B2 (ja) 2007-10-10 2008-10-03 置換ビフェニルgpr40調節因子

Country Status (19)

Country Link
US (1) US8030354B2 (https=)
EP (1) EP2205548A1 (https=)
JP (1) JP5591706B2 (https=)
KR (1) KR20100090249A (https=)
CN (1) CN102083783A (https=)
AR (1) AR068840A1 (https=)
AU (1) AU2008311355B2 (https=)
BR (1) BRPI0818253A2 (https=)
CA (1) CA2702047C (https=)
CL (1) CL2008002997A1 (https=)
CO (1) CO6270312A2 (https=)
CR (1) CR11420A (https=)
IL (1) IL204635A0 (https=)
MA (1) MA31841B1 (https=)
MX (1) MX2010003876A (https=)
PE (1) PE20091222A1 (https=)
TN (1) TN2010000125A1 (https=)
TW (1) TW200927091A (https=)
WO (1) WO2009048527A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068756A1 (es) 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN104710381A (zh) 2009-12-25 2015-06-17 持田制药株式会社 新的3-羟基-5-芳基异噻唑衍生物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2526124T3 (es) * 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
CN102617501A (zh) * 2011-01-31 2012-08-01 中国科学院上海药物研究所 取代正戊酰胺类化合物、其制备方法及用途
RU2013152631A (ru) 2011-04-27 2015-06-10 Мотида Фармасьютикал Ко., Лтд. Новое 3-гидроксиизотиазол-1-окидное производное
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013122028A1 (ja) * 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
JP6121339B2 (ja) * 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
KR20140138243A (ko) * 2012-02-28 2014-12-03 피라말 엔터프라이지즈 리미티드 G 단백질 연결 수용체 작용물질로서의 페닐알칸산 유도체
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
RS55363B1 (sr) 2012-11-16 2017-03-31 Bristol Myers Squibb Co Dihidropirazolni gpr40 modulatori
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
KR20150127208A (ko) * 2013-03-14 2015-11-16 브리스톨-마이어스 스큅 컴퍼니 비시클로 [2.2.1] 산 gpr120 조절제
CN104059039B (zh) * 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
PL3031799T3 (pl) * 2013-08-09 2018-09-28 Takeda Pharmaceutical Company Limited Związek aromatyczny
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
EP3068768B1 (en) 2013-11-15 2019-07-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
WO2018181847A1 (ja) 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
US11225471B2 (en) 2017-11-16 2022-01-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20220152164A1 (en) * 2019-03-22 2022-05-19 Kallyope, Inc. Gpcr combination therapies
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
US20240002354A1 (en) * 2020-08-05 2024-01-04 Rezubio Pharmaceuticals Co., Ltd Antidiabetic compounds and compositions
US20250223281A1 (en) * 2022-01-14 2025-07-10 Rezubio Pharmaceuticals Co., Ltd Antidiabetic compounds and compositions
CN119998290A (zh) 2022-10-03 2025-05-13 公立大学法人横滨市立大学 具有二环性结构的咪唑并吡啶衍生物
WO2024164915A1 (en) * 2023-02-07 2024-08-15 Rezubio Pharmaceuticals Co., Ltd Conjugate compounds and compositions
EP4682145A1 (en) * 2023-03-14 2026-01-21 Cascade Pharmaceuticals, Inc. Benzoheterocyclic compound, and preparation method therefor and use thereof
CN117603029B (zh) * 2023-11-21 2025-12-19 江苏禾本生化有限公司 一种戊菌唑关键中间体的合成方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE305216B (https=) 1965-09-17 1968-10-21 Astra Apotekarnes Kem Fab
FR2359135A1 (fr) 1976-07-22 1978-02-17 Hexachimie Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique
US4760089A (en) 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
PT85081A (en) 1986-06-19 1987-07-01 Smithkline Beckman Corp Irreversible dopamine-beta-hydroxylase inhibitors
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
DE4019307A1 (de) 1990-06-16 1991-12-19 Bayer Ag 2-methoximinocarbonsaeureester
JPH07508039A (ja) 1992-05-20 1995-09-07 メルク エンド カンパニー インコーポレーテッド 4−アザステロイドのエステル誘導体
US5536727A (en) 1992-05-20 1996-07-16 Merck & Co., Inc. 17-Ethers and thioethers of 4-aza-steroids
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP3894949B2 (ja) 1993-06-30 2007-03-22 ザ、ウェルカム、ファンデーション、リミテッド 抗アテローム性動脈硬化症ジアリール化合物
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
AU6490396A (en) 1995-07-14 1997-02-18 Smithkline Beecham Corporation Substituted-pent-4-ynoic acids
US5795900A (en) 1995-10-03 1998-08-18 Abbott Laboratories Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
JPH10316641A (ja) 1997-03-14 1998-12-02 Sankyo Co Ltd カルボン酸誘導体
WO1999011255A1 (en) 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19941567A1 (de) 1998-09-05 2000-04-20 Merck Patent Gmbh Neue flüssigkristalline Verbindungen
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
ATE263162T1 (de) 1999-05-05 2004-04-15 Aventis Pharma Ltd Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031527D0 (en) 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
WO2002053547A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
HRP20031002A2 (en) 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
JP4705756B2 (ja) 2002-02-07 2011-06-22 仁 遠藤 芳香族アミノ酸誘導体及び医薬組成物
EP1479768B1 (en) 2002-02-14 2010-04-28 Takeda Pharmaceutical Company Limited Novel screening method
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US20060148858A1 (en) 2002-05-24 2006-07-06 Tsuyoshi Maekawa 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
AU2003261935A1 (en) 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
US20060258683A1 (en) 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 3−(4−ベンジルオキシフェニル)プロパン酸誘導体
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
US7989457B2 (en) * 2004-05-28 2011-08-02 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
JP2007269630A (ja) 2004-06-23 2007-10-18 Toudai Tlo Ltd インスリン分泌促進剤
US20060003344A1 (en) 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US20080090865A1 (en) 2005-01-28 2008-04-17 Min Ge Antidiabetic Bicyclic Compounds
EP1846379B1 (en) 2005-01-31 2009-08-19 Merck & Co., Inc. Antidiabetic bicyclic compounds
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
MX2008011615A (es) 2006-03-14 2008-09-22 Amgen Inc Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2021327B1 (en) 2006-05-15 2012-04-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
WO2008054675A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators

Similar Documents

Publication Publication Date Title
JP2011500562A5 (https=)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2012505896A5 (https=)
JP2021534124A5 (https=)
KR102122244B1 (ko) 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
ES2281565T3 (es) Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida.
KR20090040923A (ko) Bcl 단백질과 결합 파트너의 상호작용을 억제하기 위한 화합물 및 방법
JP2016505536A5 (https=)
JP2009537524A5 (https=)
JP2013512277A5 (https=)
RU2007128987A (ru) 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры
JP2021533110A (ja) 癌免疫療法剤としての新規エクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ−1(ENPP1)の置換3H−イミダゾ[4,5−c]ピリジンおよび1H−ピロロ[2,3−c]ピリジンシリーズならびにインターフェロン遺伝子刺激因子(STING)調節剤
KR20170102885A (ko) 삼환성 스피로 화합물
AR056155A1 (es) Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
KR20160013072A (ko) 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법
WO2007129745A1 (ja) ヘテロアリールアミド低級カルボン酸誘導体
CA3020310A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP2019059781A5 (https=)
ES2729525T3 (es) Nuevo método para sintetizar un intermedio de Rivaroxaban, 4-{4-[(5S)-5-(aminometil)-2-oxo-1,3-oxazolidin-3-il]fenil]}morfolin-3-ona
CN105085429A (zh) 芳杂环类衍生物及其在药物上的应用
JP2015502371A5 (https=)
RU2009148821A (ru) Производные [1,10]фенантролина для лечения нейродегенеративных или гематологических заболеваний
KR101373911B1 (ko) Bcl 단백질과 결합 파트너의 상호작용을 억제하기 위한화합물 및 방법
JP2020517676A5 (https=)
JP2008530242A5 (https=)